Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.67 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17450128 | 0.87 | CDK1 (0.60) | CTSLTMIGD3ADORA2AADORA1CDK2 | |
| SCHEMBL17450124 | 0.85 | CDK1 (0.72) | CTSLTMIGD3ADORA2AADORA1CDK2 | |
| SCHEMBL17450223 | 0.82 | CDK1 (0.60) | CTSLTMIGD3ADORA2AADORA1CDK2 | |
| SCHEMBL17442999 | 0.82 | CDK1 (0.73) | CDK2CCNA2CCNA1CDK1 | |
| SCHEMBL17450224 | 0.82 | CDK1 (0.57) | CTSLTMIGD3ADORA2AADORA1CDK2 | |
| SCHEMBL17450179 | 0.81 | CDK1 (0.56) | CTSLTMIGD3ADORA2AADORA1CDK2 | |
| SCHEMBL6817859 | 0.81 | CDK1 (0.74) | CTSLTMIGD3ADORA2AADORA1CDK2 | |
| SCHEMBL31061476 | 0.81 | CTSL (1.00) | CTSL | |
| SCHEMBL17450131 | 0.78 | CTSL (0.72) | CTSLCDK2CDK1HDAC1 | |
| SCHEMBL24670403 | 0.78 | PDE5A (0.51) | CTSLTMIGD3ADORA2AADORA1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519160-B2 | Imaging agents for neural flux | SLC18A2, SLC18A3, PMP22 | CTSL 3700/4885TMIGD3 3542/4885ADORA2A 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.